{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:59:58Z","timestamp":1790888398140,"version":"4.1.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018554","name":"Science and Technology Program of Gansu Province","doi-asserted-by":"publisher","award":["22JR5RA1018"],"award-info":[{"award-number":["22JR5RA1018"]}],"id":[{"id":"10.13039\/501100018554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82560153"],"award-info":[{"award-number":["82560153"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["24ZYQA050"],"award-info":[{"award-number":["24ZYQA050"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Pathogenesis and Therapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.cpt.2026.03.001","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T06:59:21Z","timestamp":1774940361000},"page":"383-392","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["From fusion partner to clinical practice: A treatment-oriented framework for transcription factor E3 (TFE3)-rearranged renal cell carcinoma"],"prefix":"10.1016","volume":"4","author":[{"given":"Jiangwei","family":"Man","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1151-5942","authenticated-orcid":false,"given":"Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpt.2026.03.001_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.110190","article-title":"Integrative clinical and molecular characterization of translocation renal cell carcinoma","volume":"38","author":"Bakouny","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.cpt.2026.03.001_bib2","doi-asserted-by":"crossref","first-page":"384","DOI":"10.32074\/1591-951X-N1518","article-title":"TFE3-rearranged and TFEB-altered renal cell carcinoma: from classification to real-life. Insights from a national Italian survey","volume":"117","author":"Marletta","year":"2025","journal-title":"Pathologica"},{"key":"10.1016\/j.cpt.2026.03.001_bib3","first-page":"8","article-title":"What's new in the WHO 2022 classification of kidney tumours?","volume":"115","author":"Alaghehbandan","year":"2022","journal-title":"Pathologica"},{"key":"10.1016\/j.cpt.2026.03.001_bib4","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.eururo.2005.11.035","article-title":"2004 WHO classification of the renal tumors of the adults","volume":"49","author":"Lopez-Beltran","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.cpt.2026.03.001_bib5","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","article-title":"The 2016 WHO classification of tumours of the urinary system and male genital organs\u2014part A: renal, penile, and testicular tumours","volume":"70","author":"Moch","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.cpt.2026.03.001_bib6","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12894-025-01908-2","article-title":"Diagnosis and management of TFE3-rearranged renal cell carcinoma: case report and literature review","volume":"25","author":"Zhang","year":"2025","journal-title":"BMC Urol"},{"key":"10.1016\/j.cpt.2026.03.001_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100404","article-title":"Molecular characterization of TFE3-rearranged renal cell carcinoma: a comparative study with papillary and clear cell renal cell carcinomas","volume":"37","author":"Wei","year":"2024","journal-title":"Mod Pathol"},{"key":"10.1016\/j.cpt.2026.03.001_bib8","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1038\/s12276-024-01291-2","article-title":"Comprehensive molecular characterization of TFE3-rearranged renal cell carcinoma","volume":"56","author":"Lee","year":"2024","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.cpt.2026.03.001_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.115539","article-title":"TFE3 fusion oncoprotein condensates drive transcriptional reprogramming and cancer progression in translocation renal cell carcinoma","volume":"44","author":"So","year":"2025","journal-title":"Cell Rep"},{"key":"10.1016\/j.cpt.2026.03.001_bib10","doi-asserted-by":"crossref","first-page":"8712","DOI":"10.1038\/s41467-025-63761-z","article-title":"RNA-mediated condensation of TFE3 oncofusions facilitates transcriptional hub formation to promote translocation renal cell carcinoma","volume":"16","author":"Guo","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.cpt.2026.03.001_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102558","article-title":"Clinico-pathological implications of the 2022 WHO Renal Cell Carcinoma classification","volume":"116","author":"Rizzo","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.cpt.2026.03.001_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.humpath.2025.105797","article-title":"Evaluation of 3,606 renal cell tumors for TFE3 rearrangements and TFEB alterations via fluorescence in situ hybridization, next generation sequencing, and GPNMB immunohistochemistry","volume":"159","author":"Whaley","year":"2025","journal-title":"Hum Pathol"},{"key":"10.1016\/j.cpt.2026.03.001_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2024.101335","article-title":"The molecular code of kidney cancer: a path of discovery for gene mutation and precision therapy","volume":"101","author":"Xie","year":"2025","journal-title":"Mol Aspect Med"},{"key":"10.1016\/j.cpt.2026.03.001_bib14","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1007\/s00345-025-05927-4","article-title":"Clinical characteristics and survival outcomes of TFE3-rearranged renal cell carcinoma: a retrospective study compared with clear cell renal cell carcinoma using propensity score matching","volume":"43","author":"Han","year":"2025","journal-title":"World J Urol"},{"key":"10.1016\/j.cpt.2026.03.001_bib15","series-title":"A genetic basis for cancer sex differences revealed in Xp11 translocation renal cell carcinoma","author":"Achom","year":"2023"},{"key":"10.1016\/j.cpt.2026.03.001_bib16","doi-asserted-by":"crossref","first-page":"5735","DOI":"10.1016\/j.cell.2024.07.038","article-title":"A genetic basis for sex differences in Xp11 translocation renal cell carcinoma","volume":"187","author":"Achom","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.cpt.2026.03.001_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-65303-z","article-title":"Comparative transcriptome atlas as an assistive modality for complex classification of rare kidney cancers","volume":"16","author":"Jikuya","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.cpt.2026.03.001_bib18","doi-asserted-by":"crossref","first-page":"7649","DOI":"10.3390\/ijms23147649","article-title":"MiTF\/TFE translocation renal cell carcinomas: from clinical entities to molecular insights","volume":"23","author":"Simonaggio","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cpt.2026.03.001_bib19","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12943-024-02044-5","article-title":"Patients with ASPSCR1-TFE3 fusion achieve better response to ICI based combination therapy among TFE3-rearranged renal cell carcinoma","volume":"23","author":"Zhao","year":"2024","journal-title":"Mol Cancer"},{"key":"10.1016\/j.cpt.2026.03.001_bib20","doi-asserted-by":"crossref","first-page":"5262","DOI":"10.1038\/s41467-021-25618-z","article-title":"Integrated exome and RNA sequencing of TFE3-translocation renal cell carcinoma","volume":"12","author":"Sun","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.cpt.2026.03.001_bib21","doi-asserted-by":"crossref","first-page":"7494","DOI":"10.1038\/s41467-022-34460-w","article-title":"Proteogenomic characterization of MiT family translocation renal cell carcinoma","volume":"13","author":"Qu","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.cpt.2026.03.001_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2025.100873","article-title":"TRIM63 overexpression in FISH-negative MiTF family altered renal cell carcinoma (MiTF RCC)","volume":"38","author":"Mannan","year":"2025","journal-title":"Mod Pathol"},{"key":"10.1016\/j.cpt.2026.03.001_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.humpath.2025.105862","article-title":"Diagnostic accuracy of TRIM63 RNA-ISH in MiTF-rearranged renal cell carcinomas: results from a 331-tumor validation cohort","volume":"161","author":"Lee","year":"2025","journal-title":"Hum Pathol"},{"key":"10.1016\/j.cpt.2026.03.001_bib24","doi-asserted-by":"crossref","first-page":"6438","DOI":"10.21037\/tcr-24-60","article-title":"Management of translocation carcinomas of the kidney","volume":"13","author":"Ged","year":"2024","journal-title":"Transl Cancer Res"},{"key":"10.1016\/j.cpt.2026.03.001_bib25","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.3390\/cancers16193396","article-title":"TFE3-rearranged tumors of the kidney: an emerging conundrum","volume":"16","author":"Calio","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cpt.2026.03.001_bib26","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1080\/15548627.2020.1831815","article-title":"PRCC-TFE3 fusion-mediated PRKN\/parkin-dependent mitophagy promotes cell survival and proliferation in PRCC-TFE3 translocation renal cell carcinoma","volume":"17","author":"Wang","year":"2021","journal-title":"Autophagy"},{"key":"10.1016\/j.cpt.2026.03.001_bib27","doi-asserted-by":"crossref","first-page":"bgaf080","DOI":"10.1093\/carcin\/bgaf080","article-title":"Dual activation of autophagy and mTOR by TFE3 fusions promotes tumorigenesis in rearranged renal cell carcinoma","volume":"46","author":"Wu","year":"2025","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.cpt.2026.03.001_bib28","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1038\/s41467-024-45280-5","article-title":"ASPSCR1-TFE3 reprograms transcription by organizing enhancer loops around hexameric VCP\/p97","volume":"15","author":"Pozner","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.cpt.2026.03.001_bib29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.chembiol.2022.12.007","article-title":"Inhibitors of the ATPase p97\/VCP: from basic research to clinical applications","volume":"30","author":"Kilgas","year":"2023","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.cpt.2026.03.001_bib30","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/s13046-023-02837-4","article-title":"LncRNA like NMRK2 mRNA functions as a key molecular scaffold to enhance mitochondrial respiration of NONO-TFE3 rearranged renal cell carcinoma in an NAD(+) kinase-independent manner","volume":"42","author":"Chen","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.cpt.2026.03.001_bib31","doi-asserted-by":"crossref","DOI":"10.1177\/17588359251345722","article-title":"Recent progress in non-clear cell renal cell carcinoma: biology and therapeutic strategies","volume":"17","author":"Yildirim","year":"2025","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.cpt.2026.03.001_bib32","article-title":"Comprehensive proteogenomic characterization of rare kidney tumors","volume":"5","author":"Li","year":"2024","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.cpt.2026.03.001_bib33","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41379-021-00737-6","article-title":"Novel, emerging and provisional renal entities: the Genitourinary Pathology Society (GUPS) update on renal neoplasia","volume":"34","author":"Trpkov","year":"2021","journal-title":"Mod Pathol"},{"key":"10.1016\/j.cpt.2026.03.001_bib34","article-title":"Clinical and pathological heterogeneity of four common fusion subtypes in Xp11.2 translocation renal cell carcinoma","volume":"13","author":"Guo","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.cpt.2026.03.001_bib35","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/PAP.0000000000000332","article-title":"Chameleon TFE3-translocation RCC and how gene partners can change morphology: accurate diagnosis using contemporary modalities","volume":"29","author":"Tretiakova","year":"2022","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.cpt.2026.03.001_bib36","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s00428-022-03380-x","article-title":"TFE3 and TFEB-rearranged renal cell carcinomas: an immunohistochemical panel to differentiate from common renal cell neoplasms","volume":"481","author":"Calio","year":"2022","journal-title":"Virchows Arch"},{"key":"10.1016\/j.cpt.2026.03.001_bib37","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1158\/0008-5472.CAN-23-1789","article-title":"TFE3-splicing factor fusions represent functional drivers and druggable targets in translocation renal cell carcinoma","volume":"84","author":"Damayanti","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.cpt.2026.03.001_bib38","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1038\/s41388-025-03577-9","article-title":"NMRK2 leads to the depletion of CD8(+)T cells by mediating the enhancement of NAD(+)-SIRT1-CD38 axis in PRCC-TFE3 rRCC","volume":"44","author":"Chen","year":"2025","journal-title":"Oncogene"},{"key":"10.1016\/j.cpt.2026.03.001_bib39","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.5858\/arpa.2023-0483-CP","article-title":"Principles of analytic validation of immunohistochemical assays: guideline update","volume":"148","author":"Goldsmith","year":"2024","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.cpt.2026.03.001_bib40","article-title":"The suitability of NONO-TFE3 dual-fusion FISH assay as a diagnostic tool for NONO-TFE3 renal cell carcinoma","volume":"10","author":"Liu","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.cpt.2026.03.001_bib41","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1038\/s41379-021-00858-y","article-title":"Diagnostic utility of one-stop fusion gene panel to detect TFE3\/TFEB gene rearrangement and amplification in renal cell carcinomas","volume":"34","author":"Harada","year":"2021","journal-title":"Mod Pathol"},{"key":"10.1016\/j.cpt.2026.03.001_bib42","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.jmoldx.2023.09.007","article-title":"Clinical validation of fusionplex RNA sequencing and its utility in the diagnosis and classification of hematologic neoplasms","volume":"25","author":"Chen","year":"2023","journal-title":"J Mol Diagn"},{"issue":"8","key":"10.1016\/j.cpt.2026.03.001_bib43","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1038\/s12276-024-01291-2","article-title":"Comprehensive molecular characterization of TFE3- rearranged renal cell carcinoma","volume":"56","author":"Lee","year":"2024","journal-title":"Exp Mol Med."},{"key":"10.1016\/j.cpt.2026.03.001_bib44","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.euo.2023.10.018","article-title":"Clinical application of digital and computational pathology in renal cell carcinoma: a systematic review","volume":"7","author":"Khene","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.cpt.2026.03.001_bib45","article-title":"Digital pathology and artificial intelligence in renal cell carcinoma focusing on feature extraction: a literature review","volume":"15","author":"Li","year":"2025","journal-title":"Front Oncol"},{"key":"10.1016\/j.cpt.2026.03.001_bib46","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1038\/s41467-020-15671-5","article-title":"Computational analysis of pathological images enables a better diagnosis of TFE3 Xp11.2 translocation renal cell carcinoma","volume":"11","author":"Cheng","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.cpt.2026.03.001_bib47","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/his.70039","article-title":"Molecularly defined renal cell carcinomas: practical approaches for surgical pathologists","volume":"88","author":"Akgul","year":"2026","journal-title":"Histopathology"},{"key":"10.1016\/j.cpt.2026.03.001_bib48","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3390\/curroncol32060359","article-title":"Molecular genetics of renal cell carcinoma: a narrative review focused on clinical relevance","volume":"32","author":"Millan","year":"2025","journal-title":"Curr Oncol"},{"key":"10.1016\/j.cpt.2026.03.001_bib49","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/annonc\/mdq029","article-title":"Targeted agents in metastatic Xp11 translocation\/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network","volume":"21","author":"Malouf","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cpt.2026.03.001_bib50","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","article-title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cpt.2026.03.001_bib51","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.3390\/cancers17182945","article-title":"Harnessing p97\/VCP: a transformative AAA+ ATPase target for next-generation cancer therapeutics","volume":"17","author":"Carrera Espinoza","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cpt.2026.03.001_bib52","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41392-024-02070-1","article-title":"Emerging regulatory mechanisms and functions of biomolecular condensates: implications for therapeutic targets","volume":"10","author":"Jeon","year":"2025","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.cpt.2026.03.001_bib53","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1136\/jclinpath-2020-207372","article-title":"Diagnostic approach in TFE3-rearranged renal cell carcinoma: a multi-institutional international survey","volume":"74","author":"Akgul","year":"2021","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.cpt.2026.03.001_bib54","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/s42004-024-01267-3","article-title":"Mechanism of allosteric inhibition of human p97\/VCP ATPase and its disease mutant by triazole inhibitors","volume":"7","author":"Nandi","year":"2024","journal-title":"Commun Chem"},{"key":"10.1016\/j.cpt.2026.03.001_bib55","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12014-024-09452-1","article-title":"Recent developments in mass-spectrometry-based targeted proteomics of clinical cancer biomarkers","volume":"21","author":"Wenk","year":"2024","journal-title":"Clin Proteom"},{"key":"10.1016\/j.cpt.2026.03.001_bib56","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ccell.2025.12.009","article-title":"Spatial omics at the forefront: emerging technologies, analytical innovations, and clinical applications","volume":"44","author":"Liu","year":"2026","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cpt.2026.03.001_bib57","article-title":"Collaborating across sectors in service of open science, precision oncology, and patients: an overview of the AACR Project GENIE (Genomics Evidence Neoplasia Information Exchange) Biopharma Collaborative (BPC)","volume":"7","author":"Acebedo","year":"2025","journal-title":"ESMO Real World Data Digit Oncol"},{"key":"10.1016\/j.cpt.2026.03.001_bib58","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/gcc.22985","article-title":"RBM10-TFE3 fusions: a FISH-concealed anomaly in adult renal cell carcinomas displaying a variety of morphological and genomic features: comprehensive study of six novel cases","volume":"60","author":"Di Mauro","year":"2021","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.cpt.2026.03.001_bib59","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrurol.2014.162","article-title":"Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers","volume":"11","author":"Kauffman","year":"2014","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.cpt.2026.03.001_bib60","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/gcc.22798","article-title":"Gene fusion analysis in renal cell carcinoma by FusionPlex RNA-sequencing and correlations of molecular findings with clinicopathological features","volume":"59","author":"Tretiakova","year":"2019","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.cpt.2026.03.001_bib61","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.humpath.2023.03.008","article-title":"Cystic MED15::TFE3 translocation renal cell carcinoma: histologic mimicker of multilocular cystic renal neoplasm of low malignant potential with review of the literature","volume":"136","author":"Doytcheva","year":"2023","journal-title":"Hum Pathol"},{"key":"10.1016\/j.cpt.2026.03.001_bib62","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/s41379-018-0191-7","article-title":"NEAT1-TFE3 and KAT6A-TFE3 renal cell carcinomas, new members of MiT family translocation renal cell carcinoma","volume":"32","author":"Pei","year":"2019","journal-title":"Mod Pathol"},{"key":"10.1016\/j.cpt.2026.03.001_bib63","doi-asserted-by":"crossref","DOI":"10.1002\/cncy.22933","article-title":"Cytomorphology and clinicopathologic correlation of TFE3-rearranged renal cell carcinoma","volume":"133","author":"Hou","year":"2025","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.cpt.2026.03.001_bib64","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00345-024-05290-w","article-title":"Prognostic implications and diagnostic significance of TFE3 rearrangement in renal cell carcinoma","volume":"42","author":"Mu\u00f1oz Bastidas","year":"2024","journal-title":"World J Urol"},{"key":"10.1016\/j.cpt.2026.03.001_bib65","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1186\/s12885-025-14186-w","article-title":"Development and application of a whole transcriptome sequencing assay for the detection of gene fusions in clinical cancer specimens","volume":"25","author":"Zhao","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.cpt.2026.03.001_bib66","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jmoldx.2023.11.003","article-title":"An exome capture-based RNA-sequencing assay for genome-wide identification and prioritization of clinically important fusions in pediatric tumors","volume":"26","author":"Buckley","year":"2024","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.cpt.2026.03.001_bib67","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1038\/s41467-023-37049-z","article-title":"ASPSCR1::TFE3 orchestrates the angiogenic program of alveolar soft part sarcoma","volume":"14","author":"Tanaka","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.cpt.2026.03.001_bib68","series-title":"TFE3 fusions direct an oncogenic transcriptional program that drives OXPHOS and unveils vulnerabilities in translocation renal cell carcinoma","author":"Li","year":"2024"}],"container-title":["Cancer Pathogenesis and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949713226000212?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949713226000212?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:25:58Z","timestamp":1790886358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949713226000212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":68,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2949713226000212"],"URL":"https:\/\/doi.org\/10.1016\/j.cpt.2026.03.001","relation":{},"ISSN":["2949-7132"],"issn-type":[{"value":"2949-7132","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From fusion partner to clinical practice: A treatment-oriented framework for transcription factor E3 (TFE3)-rearranged renal cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Cancer Pathogenesis and Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpt.2026.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V. on behalf of Chinese Medical Association (CMA).","name":"copyright","label":"Copyright"}]}}